BioWa has announced that it has licensed from Kyowa Hakko Kogyo Co., Ltd., its parent company, the exclusive worldwide rights except Asia to develop and commercialize Anti-Fibroblast Growth Factor 8 (FGF8) monoclonal antibody, a potential treatment for breast, ovarian and prostate cancers.
Under the terms of the agreement, BioWa expects to develop and commercialize anti-FGF8 antibody, which is currently in pre-clinical development.
In return, Kyowa Hakko Kogyo Co. has an option to develop and commercialize the product in Asia and will be responsible for all development activities and costs.
Under the terms of the agreement, BioWa retains all rights to anti-FGF8 antibody in non-Asia countries.
Each party has the right to use pre-clinical and clinical data generated by the other party for developing anti-FGF8 antibody in their respective territories.
“We are pleased to announce the second antibody addition to BioWa's pipeline of products,” said Dr. Nobuo Hanai, CEO & President of BioWa.
“BioWa is committed to building a strong antibody pipeline of large market value products through our own internal clinical development programs.”
“Anti-FGF8 antibody is an important addition to BioWa's portfolio, which now consists of two pre-clinical stage products being investigated across a broad range of indications.”